1. "Solid Tumor Oncology Division"
Formats
  1. Journal Article (10831)
  2. Meeting Abstract (9435)
  3. Review (542)
  4. Book Section (410)
  5. Editorial (324)
  6. Guidelines (154)
  7. Correspondence (115)
  8. Conference Paper (106)
  9. Research Letter (60)
  10. Miscellaneous (53)
  11. Book Whole (27)
Groups
  1. Solid Tumor Oncology Division (22057)
  2. Department of Medicine (22035)
  3. GSK Faculty (5880)
  4. Genitourinary Oncology Service (5608)
  5. Survivorship Research (5184)
  6. Gastrointestinal Oncology Service (4640)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. Clifford Hudis (905)
  4. Jedd Wolchok (905)
  5. Mark Kris (869)
  6. Leonard Saltz (790)

More People

Years
  1. 2025 (445)
  2. 2024 (1382)
  3. 2023 (1380)
  4. 2022 (1573)
  5. 2021 (1517)
  6. 2020 (1535)

More Years

Publications
  1. Journal of Clinical Oncology (5227)
  2. Annals of Oncology (1294)
  3. Cancer Research (1012)
  4. Clinical Cancer Research (768)
  5. Journal of Thoracic Oncology (530)
  6. Gynecologic Oncology (441)

More Publications

Publishers
  1. American Society of Clinical Oncology (5507)
  2. Elsevier Inc. (2651)
  3. American Association for Cancer Research (2316)
  4. Oxford University Press (1810)
  5. Nature Publishing Group (1026)
  6. Springer (975)

More Publishers

Results (22057)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Tivozanibenivolumab vs tivozanib monotherapy in patients with renal cell carcinoma (RCC) following 1 or 2 prior therapies including an immune checkpoint inhibitor (ICI): Results of the phase III TiNivo-2 study
    Meeting Abstract

    Choueiri, T. K.; Motzer, R. J.; Beckermann, K.; Barthelemy, P.; Iacovelli, R.; Emambux, S.; Molina Cerrillo, J.; Garmezy, B.; Coelho Barata, P. M.; McKay, R. R.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Updated efficacy and safety from the phase II PHAROS study of encorafenib plus binimetinib in patients with BRAF V600E-mutant metastatic NSCLC (mNSCLC)
    Meeting Abstract

    Riely, G. J.; Ahn, M. J.; Clarke, J.; Dagogo-Jack, I.; Felip, E.; Gelsomino, F.; Goldman, J. W.; Hussein, M.; Johnson, M. L.; Morgensztern, D.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Updated efficacy and safety of vimseltinib in patients (pts) with tenosynovial giant cell tumor (TGCT): One-year follow-up from the MOTION phase III trial
    Meeting Abstract

    Gelderblom, H.; Bhadri, V. A.; Stacchiotti, S.; Bauer, S.; Wagner, A. J.; van de Sande, M.; Bernthal, N. M.; Lopez Pousa, A.; Abdul Razak, A. R.; Italiano, A.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Final overall survival (OS) in patients (pts) with newly diagnosed advanced ovarian cancer (aOC) treated with niraparib (nir) first-line (1L) maintenance: Results from PRIMA/ENGOT-OV26/GOG-3012
    Meeting Abstract

    González-Martín, A.; Pothuri, B.; Ginesta, M. P. B.; Graybill, W. S.; Vergote, I. B.; McCormick, C.; Mirza, M. R.; Moore, R. G.; Lorusso, D.; O'Cearbhaill, R. E.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • First-in-human results of STX-478, a mutant-selective PI3Ka inhibitor, in advanced solid tumor patients
    Meeting Abstract

    Montero, A. J.; Giordano, A.; Jhaveri, K.; Munster, P.; Rodon, J.; Lorusso, P.; Orr, D.; Bartolomé Arcilla, J.; Italiano, A.; Elias, A.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • SOLARIS (Alliance A021703): A multicenter double-blind phase III randomized clinical trial (RCT) of vitamin D (VitD) combined with standard chemotherapy plus bevacizumab (bev) in patients (pts) with previously untreated metastatic colorectal cancer (mCRC)
    Meeting Abstract

    Ng, K.; Ou, F. S.; Zemla, T.; McCleary, N.; Kalyan, A.; Shusterman, M.; Vijayvergia, N.; Wu, C.; Cohen, S. A.; Pulsipher, S.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Capivasertib (C) plus paclitaxel (P) as first-line treatment of metastatic triple-negative breast cancer (mTNBC): The CAPItello-290 phase III trial
    Meeting Abstract

    Schmid, P.; McArthur, H. L.; Cortés, J.; Xu, B.; Cardoso, F.; Casalnuovo, M. L.; Demirci, U.; Freitas, R.; Ghosh, J.; Hegg, R.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • NALIRIFOX versus FOLFOX as first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC): Real-world comparative overall (OS) survival analysis
    Meeting Abstract

    O'Reilly, E.; Li, J.; DerSarkissian, M.; Chang, R.; Cheng, M.; Yu, L.; Rane, D.; Zhang, L.; Xiao, Z.; Benzaghou, F.; more...
    Pharmacoepidemiology and Drug Safety (2024)

    Fulltext@MSK | Save
  • High WEE1 expression correlates with poor survival in multiple myeloma, independent of standard prognostic factors
    Meeting Abstract

    Simhal, A. K.; Firestone, R. S.; Oh, J. H.; Norton, L.; Hultcrantz, M.; Usmani, S. Z.; Maclachlan, K. H.; Deasy, J. O.
    Blood (2024)

    Fulltext@MSK | Save
  • Expanded genome-wide association study (GWAS) identifies nine novel germline risk loci for waldenström macroglobulinemia (WM) and lymphoplasmacytic lymphoma (LPL)
    Meeting Abstract

    Park, H.; McMaster, M. L.; Hunter, Z. R.; Clay-Gilmour, A. I.; Sucheston-Campbell, L. E.; Breeze, C.; Arias, J.; Davídsson, Ó. B.; Smith-Byrne, K.; Güler, M.; more...
    Blood (2024)

    Fulltext@MSK | Save